Kiora Pharmaceuticals (KPRX) Non-Current Deferred Tax Liability (2016 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Non-Current Deferred Tax Liability came in at $102152.0 in Q1 2026, down 79.18% YoY from $490690.0 in Q1 2025, and little changed on a QoQ basis from $102152.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Non-Current Deferred Tax Liability (2016 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 11 years of Non-Current Deferred Tax Liability data on file, last reported at $102152.0 in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability fell 79.18% year-over-year to $102152.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $102152.0 (down 79.18% YoY) and the FY2025 annual result came in at $102152.0, down 79.18% from the prior year.
- Non-Current Deferred Tax Liability steadied at $102152.0 in Q1 2026, from $102152.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $802131.0 in Q1 2022 to a low of $102152.0 in Q4 2025.
- A 5-year average of $614570.6 and a median of $689121.0 in 2022 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability advanced 13.11% — and 2025, when it tumbled 79.18%.
- Tracing KPRX's Non-Current Deferred Tax Liability over 5 years: stood at $689121.0 in 2022, then increased by 13.11% to $779440.0 in 2023, then plunged by 37.05% to $490690.0 in 2024, then plunged by 79.18% to $102152.0 in 2025, then changed by 0.0% to $102152.0 in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $102152.0 (Q1 2026), $102152.0 (Q4 2025), and $490690.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102,152.00 |
| Jun 30, 2026 | 102,152.00 |
| Mar 31, 2026 | 102,152.00 |
| Mar 31, 2026 | 102,152.00 |
| Dec 31, 2025 | 102,152.00 |
| Dec 31, 2025 | 102,152.00 |
| Sep 30, 2025 | 490,690.00 |
| Sep 30, 2025 | 490,690.00 |
| Jun 30, 2025 | 490,690.00 |
| Jun 30, 2025 | 490,690.00 |
| Mar 31, 2025 | 490,690.00 |
| Mar 31, 2025 | 490,690.00 |
| Dec 31, 2024 | 490,690.00 |
| Dec 31, 2024 | 490,690.00 |
| Sep 30, 2024 | 779,440.00 |
| Sep 30, 2024 | 779,440.00 |
| Jun 30, 2024 | 779,440.00 |
| Jun 30, 2024 | 779,440.00 |
| Mar 31, 2024 | 779,440.00 |
| Mar 31, 2024 | 779,440.00 |